Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide was approved in 2010 by the US Food and Drug Administration (FDA) as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This article provides insights into the use of pharmacometric analyses for regulatory review with a focus on the dosing recommendations. The assessment was based on the totality of exploratory and confirmatory analysis of dose‐finding and pivotal clinical data and was structured around a set of key questions in accordance with current FDA review practice. For the pharmacometric review of liraglutide, the key questions focused on exposure‐response relationships for effects on fasting plasma glucose, hemoglobin A 1c, and calcitonin and on variability in exposure across demographic subgroups of patients. The importance of conducting exploratory exposure‐response analysis and population pharmacokinetic studies in clinical drug development to support dosing recommendations is highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 2×
“The time course of reduction in HbA1c showed full effects of liraglutide after 12 weeks of treatment by liraglutide monotherapy.(8) This allowed for comparison of 12-week data with liraglutide monotherapy from the clinical dose-finding study of 12 to 14 weeks’ duration and the pivotal study of liraglutide monotherapy…”
BackgroundMethodZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“The concentration of liraglutide in plasma was determined by enzyme-linked immunosorbent assay (ELISA).(11) A total of 2970 concentration values from 458 patients exposed to liraglutide 1.”
MethodVilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Cited by
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“8 mg and including placebo) given as monotherapy [33].”
BackgroundMethodSelf-citationExposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12639 · Cited by 102
Self-citationLiraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0410-7 · Cited by 64
Self-citationChalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
“8 mg [21].”
Potential contributors to variation in weight‐loss response to liraglutide
Webster, C. M., Mittal, N., Dhurandhar, E. J., & Dhurandhar, N. V. (2023) · Obesity Reviews · doi:10.1111/obr.13568 · Cited by 19
Metadata
- Authors
- Ingwersen, S. H., Khurana, M., Madabushi, R., Watson, E., Jonker, D. M., Thi, T. D. L., Jacobsen, L. V., & Tornøe, C. W.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-12
- Volume
- 52
- Issue
- 12
- Pages
- 1815-1823
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2041395244
- Cited by
- 35
- References
- 6
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment. https://app.cochat.ai/papers/10.1177/0091270011430504
- The paper
- Ingwersen, S. H., Khurana, M., Madabushi, R., Watson, E., Jonker, D. M., Thi, T. D. L., Jacobsen, L. V., & Tornøe, C. W. (2012). Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011430504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.